Zachary C Dobbin
Overview
Explore the profile of Zachary C Dobbin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arend R, Londono A, Montgomery A, Smith H, Dobbin Z, Katre A, et al.
Mol Cancer Res
. 2018 Mar;
16(5):813-824.
PMID: 29523763
While high-grade serous ovarian carcinoma (HGSOC) is the most common histologic subtype of ovarian cancer, significant tumor heterogeneity exists. In addition, chemotherapy induces changes in gene expression and alters the...
2.
Cornelison R, Dobbin Z, Katre A, Jeong D, Zhang Y, Chen D, et al.
Clin Cancer Res
. 2017 Aug;
23(21):6529-6540.
PMID: 28778862
A hallmark of neoplasia is increased ribosome biogenesis, and targeting this process with RNA polymerase I (Pol I) inhibitors has shown some efficacy. We examined the contribution and potential targeting...
3.
Boone J, Dobbin Z, Straughn Jr J, Buchsbaum D
Gynecol Oncol
. 2015 Jun;
138(2):486-91.
PMID: 26026736
Preclinical research in gynecologic malignancies has largely relied upon cloned cancer-derived cell lines and tumor xenografts derived from these cell lines. Unfortunately, the use of cell lines for translational research...
4.
Erickson B, Kinde I, Dobbin Z, Wang Y, Martin J, Alvarez R, et al.
Obstet Gynecol
. 2014 Dec;
124(5):881-885.
PMID: 25437714
Objective: To investigate whether tumor cells could be detected in the vagina of women with serous ovarian cancer through TP53 analysis of DNA samples collected by placement of a vaginal...
5.
Steg A, Burke M, Amm H, Katre A, Dobbin Z, Jeong D, et al.
Oncotarget
. 2014 Sep;
5(16):7065-80.
PMID: 25216523
The goal of this study was to determine whether combined targeted therapies, specifically those against the Notch, hedgehog and ubiquitin-proteasome pathways, could overcome ovarian cancer chemoresistance. Chemoresistant ovarian cancer cells...
6.
Dobbin Z, Katre A, Steg A, Erickson B, Shah M, Alvarez R, et al.
Oncotarget
. 2014 Sep;
5(18):8750-64.
PMID: 25209969
A cornerstone of preclinical cancer research has been the use of clonal cell lines. However, this resource has underperformed in its ability to effectively identify novel therapeutics and evaluate the...
7.
Shah M, Dobbin Z, Nowsheen S, Wielgos M, Katre A, Alvarez R, et al.
Gynecol Oncol
. 2014 May;
134(2):331-7.
PMID: 24844596
Objective: BRCA-positive ovarian cancer patients derive benefit PARP inhibitors. Approximately 50% of ovarian cancer tumors have homologous recombination (HR) deficiencies and are therefore "BRCA-like," possibly rendering them sensitive to PARP...
8.
Dobbin Z, Landen C
Curr Protoc Pharmacol
. 2014 Feb;
63:14.28.1-14.28.19.
PMID: 24510756
Cancer stem cells (CSCs) are a subpopulation of cells within a heterogeneous tumor that have enhanced biologic properties, e.g., increased capacity for self-renewal, increased tumorigenicity, enhanced differentiation capacity, and resistance...
9.
Dobbin Z, Landen C
Int J Mol Sci
. 2013 Apr;
14(4):8213-27.
PMID: 23591839
Ovarian cancer is the fifth most common cause of death due to cancer in women despite being the tenth in incidence. Unfortunately, the five-year survival rate is only 45%, which...
10.
Ziebarth A, Nowsheen S, Steg A, Shah M, Katre A, Dobbin Z, et al.
Clin Cancer Res
. 2012 Nov;
19(1):170-82.
PMID: 23147994
Purpose: Endoglin (CD105) is a membranous protein overexpressed in tumor-associated endothelial cells, chemoresistant populations of ovarian cancer cells, and potentially stem cells. Our objective was to evaluate the effects and...